Hoosiers Work for Health

Hoosiers Work for Health More information is available at hoosiersworkforhealth.org.

Raising awareness among policymakers, key opinion leaders and the media of the significant social and economic value of the biopharmaceutical sector in Indiana. Hoosiers Work for Health is the Indiana chapter of a national initiative that unites health consumers, biopharmaceutical company employees, vendors, suppliers and other business and community partners to demonstrate how these diverse groups are vital to the socioeconomic climate and provide shared benefits and a better quality of life to all. Specifically, the partnership includes local chambers of commerce and research centers, labor, businesses, patient advocacy organizations, provider groups and biopharmaceutical research companies that work together to improve America’s health care system and strengthen our economy.

“Indiana is a thriving hub for biotech innovation already.” – Senator Jim Banks, Oct. 29, 2025We couldn’t agree more. In...
10/29/2025

“Indiana is a thriving hub for biotech innovation already.” – Senator Jim Banks, Oct. 29, 2025

We couldn’t agree more. Indiana’s life sciences industry drives discovery in cancer research, regenerative medicine and so much more. With over 3,200 companies, 70,000 Hoosier jobs bringing in $7.4 billion in payroll and over $1.6 billion dollars in research funding annually, Indiana is proud to be a national leader in biotechnology innovation.

Senator Banks’ focus on strengthening FDA processes, ensuring fair inspections abroad, and protecting American intellectual property is critical to supporting future innovation and investment in our state.

The U.S. can cut drug costs without killing innovation. MFN is a quick fix with big risks like shortages, fewer cures an...
09/11/2025

The U.S. can cut drug costs without killing innovation. MFN is a quick fix with big risks like shortages, fewer cures and reduced access. Let’s choose competition and smart reform through strong policy and trade talks instead.

Three months have passed since President Trump signed an executive order on “Delivering Most Favored Nation [MFN] Pricing to American Patients,” which requires that pharma reduce

Most Favored Nation (MFN) style drug pricing is not innovation friendly. Forcing U.S. pharmaceutical companies to match ...
09/04/2025

Most Favored Nation (MFN) style drug pricing is not innovation friendly. Forcing U.S. pharmaceutical companies to match Europe's low prices risks slower breakthroughs.

Republicans aren’t known for raising hell about prescription drug prices and fighting to keep them as low as possible for consumers. Call it a strength of

09/02/2025

It would be catastrophic on multiple levels if we ceded innovative superiority to our international competitors.

"It would be catastrophic on multiple levels if we ceded innovative superiority to our international competitors. Americ...
09/02/2025

"It would be catastrophic on multiple levels if we ceded innovative superiority to our international competitors. Americans would not have the same access to cutting-edge medical treatments if they are developed overseas instead of here, and the research-driven economic growth that has generated jobs nationally and here in Indiana would be significantly trimmed back."
- We Work For Health Executive Director Dan Leonard

It would be catastrophic on multiple levels if we ceded innovative superiority to our international competitors.

Address

Indianapolis, IN

Website

Alerts

Be the first to know and let us send you an email when Hoosiers Work for Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Hoosiers Work for Health:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category